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EndometriumSuccessful embryo implantation requires synchronous development and communication between the blastocyst
and the endometrium, however the mechanisms of communication in humans are virtually unknown. Recent
studies have revealed that microRNAs (miRs) are present in bodily ﬂuids and secreted by cells in culture. We
have identiﬁed that human blastocysts differentially secrete miRs in a pattern associated with their implantation
outcome. miR-661 was the most highly expressed miR in blastocyst culture media (BCM) from blastocysts that
failed to implant (non-implanted) compared to blastocysts that implanted (implanted). Our results indicate a pos-
sible role for Argonaute 1 in the transport of miR-661 in non-implanted BCM and taken up by primary human en-
dometrial epithelial cells (HEECs). miR-661 uptake by HEEC reduced trophoblast cell line spheroid attachment to
HEEC via PVRL1. Our results suggest that humanblastocysts alter the endometrial epithelial adhesion, the initiating
event of implantation, via the secretion of miR, abnormalities in which result in implantation failure.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Embryo–endometrial interactions are critical for implantation and
subsequent placental development. During the early stages of implanta-
tion, the blastocyst enters the uterine cavity, apposes and then adheres
to an adequately prepared or ‘receptive’ endometrial uterine luminal
epithelium to initiate implantation. Abnormalities in adhesion during
the very early stages of implantation result in implantation failure,
which is a major cause of infertility (Dimitriadis et al., 2005; Koot
et al., 2012). In humans, very little is known of the blastocyst–
endometrial interactions, largely due to the difﬁculty in studying im-
plantation in humans. The inﬂuence of human blastocysts on human
endometrial receptivity is largely unknown.
The conceptus enters the uterine cavity up to 72 h prior to implanta-
tion (Norwitz et al., 2001) and is thought to act on the endometrium at
least in part via soluble factors to facilitate receptivity and implantation
(Cuman et al., 2013).We have previously published that human blasto-
cysts release soluble factors that alter primary human endometrialResearch, PO Box 5152, Clayton
. Dimitriadis).
. This is an open access article underepithelial cell (HEEC) gene expression and adhesion, the initiating
event of implantation (Cuman et al., 2013).
miRs are short (~20–22 nucleotides), highly conserved sequences
that regulate the expression of 50% of genes in the human genome
(Bartel, 2004). Mature miRs act by binding to complementary regions
of mRNAs, inhibiting translation or by destabilising the gene, resulting
in down regulation of their target genes (Bohnsack et al., 2004; Chen
and Rajewsky, 2007; Kim, 2005; Lee et al., 2003). miR can be secreted
by cells, via a number of mechanisms including exosomes, apoptotic
bodies and bound to lipid or RNA binding complex (RBC) proteins, such
as Argonaute (Ago) 1 and 2 (Arroyo et al., 2011; Vickers et al., 2011).
MiRs are present not only within cells but also in body ﬂuids such as
saliva, urine, blood, plasma and cell culture media (Hanke et al., 2010;
Mitchell et al., 2008; Park et al., 2009; Zubakov et al., 2010).
Analysis of human endometrium and trophectoderm has identiﬁed
the expression of a large number of miRs (Dior et al., 2014; Galliano
and Pellicer, 2014; Kresowik et al., 2014; Rosenbluth et al., 2013), with
more recent studies demonstrating that miRs are secreted by human
and bovine embryos in culture (Kropp et al., 2014; Rosenbluth et al.,
2014). We hypothesised that miRs are released by human blastocysts
and are taken up by endometrial surface epithelial cells to regulated
endometrial receptivity and implantation. The aim was to identify miRthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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implanted compared to those that failed to implant. Furthermore, we
aimed to determine miR uptake by human endometrial epithelial cells
and the effect on adhesion and therefore identify the possible functional
consequences relevant to endometrial receptivity and implantation.
2. Materials and Methods
2.1. Ethical Approval
Human ethical approval was obtained for all the studies in this
manuscript as follows:
Endometrium collection
Written informed consent was obtained from each patient, before
surgery in the case of women with primary infertility, and protocols
were approved by the Southern Health Human Research Ethics Com-
mittee, Melbourne, Australia.
Blastocyst media collection
Written informed consent was obtained from each patient and the
study was approved by the Monash Surgical Private Hospital Human
Research Ethics Committee, Melbourne, Australia.
Trophectoderm collection
Written informed consent was obtained from each patient and
the study was approved by Monash Health (#12,101) and the Embryo
Research Licencing Committee, National Health and Medical Research
Council of Australia (#309722).
2.2. Endometrial Collection
Endometrial biopsies (n = 33) were collected at curettage from
women with regular menstrual cycles throughout the proliferative
and secretory phases of the menstrual cycle (Cuman et al., 2013; Paiva
et al., 2009; Van Sinderen et al., 2013). Thewomen had no steroid treat-
ment for at least 2 months prior to tissue collection. An experienced
gynaecological pathologist conﬁrmed biopsies showed no evidence of
possible endometrial dysfunction. Biopsies were either placed into
DMEM F/12media for further isolation or ﬁxed in Formalin. See supple-
mental experimental procedures for further details on endometrial
isolation.
2.2.1. Spent Conditioned Media (BCM)
Spent blastocyst conditioned media (BCM) were collected from
embryos (fertilised by ICSI only) that had been cultured from days 3
to 5 and stored at−80 °C. Control culture media (not exposed to an
embryo) were also collected. BCM were collected from two groups: 1.
Blastocysts that successfully implanted (clinical pregnancy carried to
term N36 weeks) (Implanted) and 2. Blastocysts that did not implant
and did not result in pregnancy (no biochemical or clinical indications)
(non-implanted).
2.2.2. Trophectoderm Collection
Human embryos consented to medical research (Ethics #12101)
were thawed, and allowed to expand with assisted hatching overnight.
Using in house technique, the inner cell mass was removed from the
embryo and allowed to succumb. The remaining trophectoderm cells
were collected directly into lysis buffer for PCR use. MicroRNA was
isolated from cells using TaqMan Cell to CT kit (Life Technologies)
according to manufactures instructions.
2.2.3. BCM microRNA Real Time PCR Arrays
RNA was isolated from BCM (10 μl) using miRCURY RNA Bioﬂuids
isolation Kit (Exiqon, Denmark) according to the manufacturer's in-
structions. cDNA synthesis and RT qPCR on BCM was performed using
the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon,
Denmark) according to the manufacturer's instructions. In brief, the
RNAwas tailedwith a poly (A) sequence at their 3′end and then reversetranscribed into cDNAusing a universal poly (T) primerwith a 3′endde-
generate anchor and a 5′end universal tag. The cDNA products were
subsequently diluted 125 fold and transferred to the ready-to-use
microRNA PCR Human Panels (I + II). The qPCRs were run on a
7900HT thermocycler (ABI) using the thermal-cycling parameters
recommended by Exiqon. Raw Ct values were calculated as recom-
mended by Exiqon using the RQ manager software v1.2.1 (ABI) with
manual settings for threshold and baseline, i.e. all miRCURY assays
were analysed using a ΔRn threshold of 60 and baseline subtraction
using cycles 1–14. Analysis was performed using the Gene Ex software.
2.2.4. Primary HEEC Isolation
Endometrial epithelial cells were prepared as previously published
(Cuman et al., 2013). Brieﬂy, endometrial tissue was digested with
collagenase and the suspension was ﬁltered through 43 and 11 mm
nylon mesh to collect endometrial epithelial glands. The cells and epi-
thelial fragments were collected and resuspended in a 1:1 mixture
of Dulbecco's modiﬁed eagle's medium (DMEM)/Hams F-12 (Gibco)
supplemented with 10% foetal calf serum (FCS; Invitrogen), and 1%
antibiotic–antimycotic? solution (Gibco, Auckland, NZ) and plated. A
purity of 95% was necessary for the cells to be used experimentally.
2.2.5. HTR-8/SVneo Trophoblast Cell Line
The HTR-8/SVneo trophoblast cell line exhibits features of invasive
trophoblast cells, such as human leukocyte antigen-G (extravillous tro-
phoblast marker) and cytokeratin-7 expression (Hannan et al., 2010).
These cellswere cultivated andmaintained inRPMI 1640 (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% FCS, as previously described
(Graham et al., 1993).
2.2.6. RNA Isolation and Quantitative PCR
RNA was extracted from cultured cells and conditioned media
(excluding BCM and primary trophectoderm cells) using Tri Reagent
(Sigma) according to the manufacturer's instructions. Isolated RNA
was reversed transcribed into complimentary DNA with M-MLV RT
system (Life Technologies) by using the TaqMan primer sets for miRs
(Applied Biosystems) or Oligo primers (sigma) for non-miRs. Real time
PCRwasperformedusing the TaqManFastUniversal PCRMastermix (Ap-
plied Biosystems) or Power SYBRGreenmastermix (Applied Biosystems)
by using TaqMan probes or speciﬁc primer pairs (MTA1, F- TAACAAGCCA
AATCCGAACC R- TCCTGGCCTCTCTCCATCTA;MTA2, F- CGGGTGGGAGAT
TACGTCTA R- TGGCTGCTTTGATTCCTCTTPVRL1 F- AATCGAGAAAGCCAGC
TCAA R- CGGATCTCCTGGTACTCTGC; EPHB2- F- GATGGGGCAGTACAAG
GAGA, R- AGGCAGGTGAATGTCAAACC). miR expression levels were nor-
malised against control snU6 probes. Expression ofMTA2 and PVRL1was
normalised against 18S and beta-actin.
2.2.7. miR Uptake by Primary HEEC
Fluorescein (FLC) tagged mIR-661 (Sigma) was transfected into
HTR8s using Lipofectamine RNAiMax at a concentration of 100 nM,
(based on the manufacturer's instructions). HTR8s were washed with
culture media 12 h post transfection and incubated with fresh culture
media for 12 h further. HTR8-CM was collected and used to treat HEECs.
A scramblemicroRNA sequence (Life Technologies)was used as a control.
HTR8 cells and 1 ml-conditioned media were collected for conﬁrmation
of overexpression of miR-661 by RT qPCR. HEECs were treated for 8 h
and uptake conﬁrmed by RTqPCR and immunoﬂuorescence (method
adapted from (Zhou et al., 2013)).
2.2.8. Immunoﬂuorescence
Visualisation of FLC-miR-661 was conﬁrmed using immunoﬂuores-
cence. Brieﬂy, HEECs were plated onto chamber slides and treated
with HTR8-CM as described above. Following treatment, media re-
moved, cells were washed and the chamber slide ﬁxed in 70% ethanol
overnight. Nuc-Red (to visualise nuclei;Invitrogen) was applied to the
slide prior to ﬁxing with ﬂuorescent mounting media (Dako).
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HTR8-CM was collected and centrifuged at 1000 g for 10 min to
remove cell debris. The supernatant was transferred to a new tube
and spun at 120,000 g for 100 min at 4 °C (Arroyo et al., 2011). The
supernatant and pellet were collected and RNA isolated to identify
miR-661 expression. HEECs were treated with the collected superna-
tant, and the pellet re-suspended in 5% FBS DMEM/F12.
2.2.10. Proteinase K Treatment
HTR8-CM was treated with proteinase K (20 μg/ml, Invitrogen)
following VESICLE separation by ultracentrifugation, at 55 °C for
15 min to digest proteins in the CM (Arroyo et al., 2011). HEECs were
treatedwith orwithout the proteinase K treatedmedia for 8 h, followed
by RNA extraction and PCR (as described above) to determine the effect
on miR-661 expression levels in HEEC.
2.2.11. Co-Immunoprecipitation
Co-immunoprecipitation was performed using 800 μl HTR8-CM or
400 μl pooled BCM 200 μl or 100 μl of lysis buffer respectively and 1 μg
of Ago1 antibody (Cell signalling technologies), Ago 2 antibody (Cell
signalling technologies) or control IgG (Dako). Following Incubation at
4 °C overnight, the immune complexes were pulled down with protein
A/G magnetic beads (Thermo Scientiﬁc) and serially washed with 0.5%
TBS/Tween, followed by TBS and distilled H2O. 500 μl of TriReagent
was added to each sample and RNA extracted as per standard protocol
described above. Method adapted from (Arroyo et al., 2011).
2.2.12. In-silico Analysis
For computational analysis, we used miRTarbase release 4.5 (Hsu
et al., 2014) and DIANA-TarBase v7.0 (Vlachos et al., 2015). A list of
the common targets was composed based on the 2 lists.
2.2.13. Immunohistochemistry
Immunohistochemistry for MTA2 and PVRL1 was performed on
endometrial tissue from fertile women across the cycle as previously
described (Cuman et al., 2013), using antibodies at the following
concentrations: MTA2 (0.5 μg/ml rabbit monocolonal, # sc-28731,
Santa Cruz) and PVRL1 (1 μg/ml mouse monocolonal, # sc-21722,
Santa Cruz). Negative isotype controls of mouse or rabbit IgG (both
DakoCytomation, Denmark) were applied at the same concentration
as the primary antibodies.
2.2.14. Western Blotting
HEEC lysates were collected using universal lysis buffer following
treatment with HTR8-CM. Western blotting was performed as pre-
viously described (Van Sinderen et al., 2013). Membranes were probed
with antibodies against MTA2 (1:500 # sc-28731, Santa Cruz), PVRL1
(1:250 # sc-21722, Santa Cruz) and GAPDH (1:5000, #3683 cell signal-
ling). Densitometry analysis was performed using Image Lab (BioRad).
2.2.15. Spheroid Adhesion Assay
To determine the effect of miR-661 on the adhesive properties
essential for the attachment of the blastocyst to the endometrium, a
co-culture model was established based on previous publication
(Krishnan et al., 2013).
HEECs were grown to conﬂuence 96-well plate and transfected
according to manufacturers instructions using Lipofectamine RNAimax,
with; miR-661 mimic only (3 pmol; Life Technologies); miR-661
mimic + miR-661 inhibitor (3 pmol; Life Technologies);miR-661
mimic + PVRL1miR script Target Protect (4.5 pmol; Qiagen) or vehicle
control for 72 h. Spheroids were formed using HTR8sv/Neo cells (2000
cells per spheroid) in a Cellstar U-shaped 96-well Suspension Culture
Plate (Greiner Bio-One) and incubated at 37 °C for 48 h. Spheroids
(8–10 perwell) were transferred into a 96-well plate containing treated
HEEC cells. Spheroid number was determined visually prior to incuba-
tion at 37 °C for 2 h. Co-culture wells were washed gently, with 150 μlserum-free DMEM/F12 media and the remaining spheroids counted to
determine the number of adhered spheroids; Attachment us expressed
as a percentage of the original spheroid number.
2.2.16. Sample Size
All sample sizes detailed have been chosen according to our previous
experience using these techniques and power calculations (G*Power).
3. Results
3.1. Human Blastocysts Secrete microRNA Relative to
Implantation Potential
To identify the proﬁle of miRs secreted by blastocysts, real-time PCR
miR arrays were used to compare BCM (pooled n= 8, Table S1, patient
sample characteristics) collected from blastocysts that successfully
implanted (implanted) compared to those which failed to implant
(non-implanted). Culture media alone were used as a control. 140
miRs (18% of total 784 on array) were detected across the three media
groups. 47miRswere detected exclusively in themedia containing a blas-
tocyst and from these 19 miRs were in the implanted group exclusively,
22 miRs in the non-implanted group exclusively and 6 miRs found in
both groups. 22 miRs were solely expressed in the control culture
media (Data not shown).miR-661, the highest differentially expressed
miR in non-implanted BCM was conﬁrmed by individual real time PCR
TaqMan assays of the pooled media sample (Fig. 1A) and its presence in
human trophectoderm cells were also conﬁrmed (Table S3). Analysis of
additional individual samples (n = 5), showed the presence of miR-661
samples speciﬁcally to the non-implanted cohort (Table 1).
3.2. miR-661, Secreted by Human Blastocysts that do not Implant is Taken
up by Primary Human Endometrial Epithelial Cells (HEECs)
To determine if HEECs can take up blastocyst secreted miRs, miR-
661 uptake was investigated in our in vitro primary human culture
models. Cultured HEECs treated with non-implanted BCM (pool of indi-
vidual BCM samples used in miR arrays) demonstrated a signiﬁcant
increase in intracellular miR-661 mRNA levels compared to treatment
with implanted BCM and control media (Fig. 1B). Investigation of
endogenous miR-661 expression in HEECs, demonstrated miR-661
expression in the cultured HEECs was detected at very low or undetect-
able levels by Real time PCR (Data not shown). To further investigate if
miRs secreted by blastocysts were taken up by primary HEEC we used
ﬂuorescently tagged synthetic miR-661 (FLC-miR-661) which was
transfected into the HTR8sv/neo (HTR8) cell line. After transfection,
the culture media were refreshed after 12 h to remove free oligonucle-
otides. The HTR8 CMwas collected 12 h after refreshment. Transfection
of HTR8 with FLC-miR-661 signiﬁcantly increased the expression of
miR-661 in HTR8 cell CM (Fig. 1C), compared to control (scrambled
miR) transfected CM. Primary HEECs were treated with the HTR8 CM
which resulted in the expression of miR-661 in HEECs compared to
undetectable miR-661 in culture media from control treated cells
(Fig. 1D). Fluorescent imaging conﬁrmed the presence of FLC-miR-661
in the cytoplasm of HEECs (Fig. 1E).
3.3. miR-661 is Secreted and Transported by Human Blastocysts via
Argonaute 1 Protein
To determine the possible mechanism bywhichmiR-661 is secreted
by blastocysts into culturemedia, ultracentrifugationwas performed on
HTR8 FLC-miR-661 CM to separate RBC proteins in the supernatant
from micro vesicles (MV) found in the remaining pellet (6). miR-661
expression was signiﬁcantly higher in the supernatant compared to
the remaining MV pellet (Fig. 2A). HEECs were treated with the total
(unspun media), supernatant CM or resuspended MV pellet. miR-661
expression signiﬁcantly increased in the HEEC treatedwith supernatant
Fig. 1.miR-661 is expressed in non-implanted BCM and HEECs take up secretedmiR-661 from conditionedmedia.A. RTqPCR validation ofmiR-661 in implanted and non-implanted BCM
vs. control media alone (n = 8, pooled). Data is normalised to endogenous snU6 and presented as mean ± SEM, * p b 0.05, Student's t test). B. HEEC treated with Pooled BCM (control,
implanted and non-implanted BCM) for 24 h increased expression of miR-661 treated with non-implanted compared to implanted and control only media (n = 4). C. Transfection
of HTRsv/neo (HTR8) cell with ﬂuorescein tagged (FLC)-miR-661, increased expression of miR-661 in HTR8 cell conditioned media (CM) compared to control (scrambled miR) CM
(n = 3). D. Uptake of FLC-miR-661 in HEEC when treated with FLC-miR-661 CM for 8 h, compared to treatment with control (scrambled miR) CM (n = 6). E. Immunoﬂuorescence of
FLC-miR-661 in HEEC. FLC-miR-661 (Green), Nuc-Red (Red). Data is presented as mean ± SEM, *p b 0.05, **p b 0.01, ****p b 0.0001, Student's t-test..
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the hypothesis that miR-661 was transported via RBC proteins, the
supernatant CMwas digested with proteinase K which signiﬁcantly de-
creased miR-661 expression in the culture media (Fig. 2C), thus
demonstrating that miR-661 was protected from digestion via itsTable 1
Individual BCM miR-661 CT levels.
Implanted Non-implanted
Undetected CT N40 31.1
Undetected CT N40 27.8
Undetected CT N40 28.6
Undetected CT N40 27.4
Undetected CT N40 26.1binding to an RBC protein. To determine the RBC protein responsible
for the transport of miR-661, co-immunoprecipitation (Co-IP) of the
supernatant CM with either Argo 1 or Argo 2 identiﬁed Ago 1, but not
Ago 2, as the carrier of miR-661 (Fig. 2D). In order to determine if the
miR-661 association with Ago 1 was not an artefact of the trophoblast
cell line, co-IP on pooled BCM (n = 270), conﬁrmed that miR-661 was
bound to Ago 1, thus indicating that human blastocysts transport
miR-661 via the RBC protein, Argo-1 (Fig. 2E).3.4. miR-661 Targets MTA2 and PVRL1 in Human Endometrial
Epithelial Cells
In silico bioinformatics analysis of validated miR-661 target genes,
identiﬁed a number of target genes that have roles in adhesion and
Fig. 2.miR-661 is bound to Argonaute 1 for extracellular transport. Expression ofmiR-661 inA. Differentially centrifugedHTR8 CM(n=3),B. HEEC, treatedwith differentially centrifuged
HTR8 CM(n=3) (TotalmiR-661 CM, supernatant onlymiR-661 CMor re-suspendedMVpellet. C. DecreasedmiR-661 expression inHEEC treatedwithHTR8-miR-661 CM+Proteinase K
(PK) compared to miR-661 CM alone. D Co-immunoprecipitation of FLC-HTR8 CM, miR-661 expression bound to Ago 1 compared to IgG control and Ago2 (n = 3). E. Expression of
miR-661 bound to Ago 1 in pooled BCM compared to IgG control (n = 1, pooled 270 samples from non-implanted BCM). Proteinase K (PK), Argonaute (Ago). Data is presented as
mean ± SEM*p b 0.05, **p b 0.01, 1-way ANOVA.
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Nectin-1), metastasis associated protein (MTA) 1 and 2 and Ephrin type-
B receptors 2 (EPHB2) expression were signiﬁcantly decreased in miR-
661 CM treated HEEC compared to control HEEC (Fig. 3A–D). PVRL1 and
MTA2 proteins were down regulated (Figs. 3 and S1) and but there was
no change in EpBH2 (data not shown). Immunohistochemistry localised
MTA2andPVRL1 to the luminal and glandular epithelium,with no chang-
es in their levels observed across themenstrual cycle in normal fertile en-
dometrial tissue (Fig. 3Fi–iv).
3.5. miR-661 Blocks Adhesion in Primary Human Endometrial Epithelial
Cells via PVRL1
To determine the role of miR-661 in implantation, an established
trophoblast spheroid-endometrial co-culture adhesion assay
(Krishnan et al., 2013)was used to investigatemiR-661 ability to inhibit
embryo–endometrial adhesion.miR-661 treated HEEC, signiﬁcantly de-
creased adhesion of spheroids to HEEC compared to vehicle only HEEC
(Fig. 4A). The addition of a miR-661 inhibitor signiﬁcantly increased
the adhesion of the spheroids to HEEC, compared to mimic treatment
only HEEC (Fig. 4A). Investigation of PVRL1, previously shown to have
a role in cell adhesion (Takai et al., 2003), signiﬁcantly increased adhe-
sion of spheroids to HEEC treated with PVRL1 target protector, which
prevents the binding of miR-661 to the 3′UTR binding site, speciﬁcally
blocking the down regulation of PVRL1 by miR-661 (Fig. 4B).
4. Discussion
This study has demonstrated that human blastocyst secreted miRs
are taken up by primary human endometrial epithelial cells and regu-
late their adhesive capacity via targeting gene and protein production.
We have identiﬁed a potential mechanism by which blastocysts com-
municate with the endometrium, which is likely to facilitate receptivityand implantation in humans. This study has identiﬁed a functional role
for blastocyst-secretedmiRs on endometrial epithelial cell adhesion, the
initiating event of implantation.
Our ﬁndings demonstrate that blastocysts secrete different miR pro-
ﬁles, in accordance with their implantation outcomes following ART. To
date two other papers have examined miR expression in human BCM.
Kropp et al., identiﬁed only one miR, miR-25, in pooled media from
day 5 and day 6 blastocysts, however no correlation was identiﬁed in
relation to blastocyst quality (Kropp et al., 2014). miR-25 was not iden-
tiﬁed in our cohort.
One other study used PCR arrays to identify miR expression proﬁles
in BCM (Rosenbluth et al., 2014). They identiﬁed two miRs solely
expressed in BCM, miR-372 and miR-191 that were not present in
control media. miR-372 was expressed in both euploid and aneuploid
BCM and was higher in BCM from embryos that failed to implant
when correlated with the use of ICSI only embryos. These results are
consistent with our ﬁnding that miR-372 was detected only in non-
implanted BCM samples. miR-191 was not included in the array panel
used in our study.
We however identiﬁed a large number of miRs that were differen-
tially secreted into BCM from implanted compared to non-implanted
BCM. The differences in the miRs detected between our study and
the previous studies are likely due to differences in the experimental
methods between the studies including differences in RNA extraction,
cDNA synthesis, miR array panels used for detecting miRs in BCMand,
differences in embryo culture media. Speciﬁcally, in our study we cul-
tured embryos for 48 h compared to 24 h, and used different media
for culture compared to a previous study (Rosenbluth et al., 2014).
This may have affected differences in the miRs detected in BCM
between the two studies. In addition, we used a miR array system that
required less BCM compared to a previous study suggesting that the
array systemwe usedwas highly sensitive whichmay have contributed
to differences in detection of speciﬁc miRs between the present and
Fig. 3.miR-661 reduces target expression in HEECs. HEEC treatedwithmiR-661 CM, signiﬁcantly decreased expression ofA.EBPH2, B. PVRL1, C.MTA1 andD.MTA2 compared to control CM
(n=3).E.Western analysis showeddecreased expression of PVRL1 andMTA2protein fromHEEC treatedwithmiR-661CMcompared to control CM. F. Immunohistochemistry (n=4/phase)
localised PVRL1 and MTA2 to glandular (G) and luminal epithelium (LE) in both proliferative and mid-secretory phase of the menstrual cycle. Data is presented as mean ± SEM, * p b 0.05,
Students t test.
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used embryos that had been frozen at the pronuclear stage, thawed
and cultured to blastocyst stage and arrays undertaken on BCM collect-
ed at the blastocyst stage (Rosenbluth et al., 2014). By comparison, in
our studywe did not freeze/thaw the embryoswhichmay have affected
the pattern of miR secretion between the present and a previous study
(Rosenbluth et al., 2014).
Extracellular miRs are released from cells in membrane bound
vesicles (such as exosomes), bound to RBC proteins (Ago1 and Ago2)
or attached to high density lipo-proteins. miRs encapsulated inFig. 4.miR-661 regulates trophoblast spheroid adhesion toHEEC.A.Decreased adhesion of HTR8
inhibitor “rescued” adhesion as it was unchanged compared to control (n = 3). B. Increased ad
compared to miR-661 mimic only (n = 5). Data is presented as mean ± SEM** p b 0.01, ***p bmembrane bound vesicles or attached to proteins, protect miRs from
RNase activity (Arroyo et al., 2011).Our study demonstrates a mecha-
nism by which human blastocysts secrete miR-661 and transport it for
uptake by the primary endometrial epithelial cells. We demonstrated
that extracellular miR-661 was bound to the RBC Ago 1 and not Ago 2
or in vesicles, a ﬁnding that has not been previously identiﬁed in any
cell type. Our study however, does not rule out whether primary HEEC
take up other miRs or any other factors present in BCM. Our data how-
ever does demonstrate that the increased miR-661 expression in the
primary HEEC occurs primarily via uptake from the media and not viaspheroids toHEEC treatedwithmiR-661mimic compared to control. Addition ofmiR-661
hesion of HTR8 spheroids to HEEC treated with miR-661 mimic and PVRL1 target protect,
0.001, 1-way ANOVA..
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the media.
It is unknown if miR transport mechanisms for speciﬁc miRs, remain
the same in all cell systems or whether a speciﬁc cell transports most
miRs via one or multiple modes. While this study shows a mechanism
of miR transport from human trophectoderm cells in vitro, it remains
to be investigated whether this is a generalised phenomenon for
most miRs secreted by human blastocysts. Studies investigating the
expression of miRs secreted by the endometrium are limited to the
capture of exosomes and the miR carried in their cargo (Kresowik
et al., 2014; Ng et al., 2013). To date no study, has examined the role
Ago proteins play in the communication between the blastocyst and
the endometrium.
Studies of the miRs in the endometrium are limited to expression
studies, comparing the expression of miRs in receptive with non-recep-
tive phase endometrium (Altmae et al., 2013; Kresowik et al., 2014;
Kuokkanen et al., 2010), or in endometrium from fertile, infertile and
repeat implantation failure (RIF) women (Dior et al., 2014; Revel et al.,
2011; Zhao et al., 2012),with the aimof identifying endometrial receptiv-
ity biomarkers. To date only one recent study, has investigated a func-
tional role of miRs in human endometrial cells in vitro, speciﬁcally
miR-145. miR-145, is a previously identiﬁed miR with high expression
in endometrium from women with repeat implantation failure (RIF)
compared to normal fertile women (Revel et al., 2011). miR-145 over-
expression in a human endometrial carcinoma cell line, was shown to
inhibit mouse embryo adhesion to the cells (Kang et al., 2015). Our
study however, provides evidence of direct uptake of a miR from
human BCM byHEEC and demonstrates a functional effect on adhesion.
Mature miRs act by destabilising mRNAs with some degree of com-
plementarity or by repressing protein translation, leading to down reg-
ulation of target genes and changes in biological functions (Bohnsack
et al., 2004; Chen and Rajewsky, 2007; Kim, 2005; Lee et al., 2003).
The expression of miRs is tightly coordinated and each miR has the
ability to act on numerous gene targets (Bartel, 2004; Chen and
Rajewsky, 2007). miR-661, is predicted to target approximately 1000
target genes (Paraskevopoulou et al., 2013; Reczko et al., 2012;
Vlachos et al., 2015), and has been experimentally veriﬁed to target 6
genes; MTA1 MTA2, STARD10, VCL and PVRL1 (also known as PVRL1)
(Hsu et al., 2014; Reczko et al., 2012; Reddy et al., 2009; Vetter et al.,
2010; Vlachos et al., 2015).
The MTA family of proteins, is a central component of the Mi-2Nurd
complex, in which their primary role is to regulate gene expression
networks, via controlling histone acetylation and by regulating key
signalling pathways by acetylation of target networks (Covington and
Fuqua, 2014; Sen et al., 2014). MTA1 has been previously shown to be
expressed in benign endometrium and in endometrial adenocarci-
nomas (Balasenthil et al., 2006) and we have identiﬁed and localised
MTA2 in human endometrial tissue. MTA2 regulates cytoskeletal orga-
nisation partly via activation of the Rho signalling pathway (Covington
and Fuqua, 2014). Whilst no studies have demonstrated a role of
MTA2 or the effects of histone acetylation in human implantation, the
Rho signalling pathway has been implicated to have a role in inducing
human trophoblast invasion and migration (Saso et al., 2012) The
downregulation of MTA2 by miR-661, may therefore inhibit activation
of MTA2 target genes, such as Rho, which are required for embryo
implantation.
PVRL1 is a membrane bound immunoglobulin-like cell adhesion
molecule and modulates cell adhesion (Takai et al., 2003; Yu et al.,
2007). It is a validated target of miR-661 breast cancer cells (Vetter
et al., 2010). We demonstrated that miR-661 signiﬁcantly down regu-
lated PVRL1 mRNA and protein in primary endometrial epithelial cells.
Nectins regulate the formation of adherens and tight junctions in
epithelial cells (Takai and Nakanishi, 2003) and participate in the regu-
lation of cellular activities such as cell polarisation, differentiation and
proliferation (Takai et al., 2003, 2008), all of which are know require-
ments for embryo implantation (Norwitz et al., 2001). This suggeststhat the repression of PVRL1 by miR-661 may contribute to the disas-
sembly of cell-cell contact and loss of epithelial cell polarity in the endo-
metrial luminal epithelium, thus creating an unstable environment for
attachment or loss of the ﬁrm adhesion required between the endome-
trium and trophectoderm for successful implantation. In this regard, we
demonstrated that miR-661 blocked HEEC adhesion, at least partly, via
PVRL1. Whilst a modest effect on adhesion was noted, there is highly
likely to be additional factors regulated by miR-661 that regulate
adhesion.
Our ﬁndings emphasise the important role that human blastocysts
have on regulating the very early stages of implantation, adhesion,
abnormalities in which lead to implantation failure and infertility. Our
data demonstrate that human blastocysts secrete miRs that likely ac-
tively participate in the implantation process. Blastocyst-secreted miR
proﬁles may thus be useful as biomarkers of their implantation poten-
tial or as targets to treat implantation failure and infertility, however
additional studies are required to explore this further.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.003.
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